Deutsche Bank’s Protalix BioTherapeutics PLX Stock Holding History

Deutsche Bank’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$163K	Buy	74,985 +74,139	+8,763%	+$184K	﹤0.01%	3090
2025 Q4	$1.52K	Sell	846 -64,771	-99%	-$132K	﹤0.01%	3592
2025 Q3	$146K	Buy	+65,617	New	+$107K	﹤0.01%	3204
2021 Q3	–	Sell	-873	Closed	-$2K	–	4611
2021 Q2	$2K	Buy	+873	New	+$3K	﹤0.01%	4549
2017 Q3	–	Sell	-33,057	Closed	-$276K	–	5032
2017 Q2	$276K	Sell	33,057 -7,562	-19%	-$71K	﹤0.01%	3760
2017 Q1	$552K	Buy	40,619 +9,519	+31%	+$85.6K	﹤0.01%	3029
2016 Q4	$138K	Hold	31,100	–	–	﹤0.01%	3900
2016 Q3	$177K	Sell	31,100 -8	-0%	-$50	﹤0.01%	3712
2016 Q2	$199K	Sell	31,108 -20	-0.1%	-$160	﹤0.01%	3777
2016 Q1	$261K	Sell	31,128 -493	-2%	-$4.22K	﹤0.01%	3527
2015 Q4	$322K	Buy	31,621 +30,541	+2,828%	+$311K	﹤0.01%	3481
2015 Q3	$12K	Buy	+1,080	New	+$17.2K	﹤0.01%	4914
2015 Q1	–	Sell	-148	Closed	-$2K	–	5751
2014 Q4	$2K	Sell	148 -26,211	-99%	-$563K	﹤0.01%	6013
2014 Q3	$637K	Buy	+26,359	New	+$759K	﹤0.01%	3327

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Deutsche Bank's PLX Position: Q1 2026 in Review

Deutsche Bank increased its Protalix BioTherapeutics (PLX) stake by 8,763% in Q1 2026, buying an estimated $184K and bringing the position to 74,985 shares worth $163K. The position accounts for ﹤0.01% of the portfolio, ranked #3090.

Deutsche Bank first reported a position in PLX in Q3 2014 and has held it in 14 quarters since. The position peaked at $637K in Q3 2014. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

Deutsche Bank held 74,985 shares of Protalix BioTherapeutics worth $163K as of Q1 2026.
Deutsche Bank bought 74,139 Protalix BioTherapeutics shares in Q1 2026, an estimated $184K.
Protalix BioTherapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #3090 holding.
Deutsche Bank first reported a position in Protalix BioTherapeutics in Q3 2014 and has held it in 14 quarters since.
Deutsche Bank's Protalix BioTherapeutics position peaked at $637K in Q3 2014.
99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.